HiCy

From Wikipedia, the free encyclopedia

HiCy (high-dose cyclophosphamide) is an experimental procedure used in the treatment of autoimmune diseases, notably multiple sclerosis. The treatment relies on the differential susceptibility of blood cells to cyclophosphamide: while progenitors are relatively insensitive to the chemical, differentiated blood cells are susceptible. The procedure obliterates the immune system, allowing the blood cell progenitors to repopulate. ^[1] For weeks following the treatment, individuals are immunocompromised.